ROSEN, A LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The complaint claims defendants provided overly positive statements while concealing material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be entitled to compensation. The lead plaintiff deadline is August 4, 2026.